Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Health
Safety Alert Released for Ozempic and Related GLP-1 Medications
S
Shotlee
Health & Wellness Team
1 min read
Preparing your Shotlee experience
A safety alert has been issued in Australia concerning GLP-1 receptor agonists like Ozempic. The alert highlights a potential connection to suicidal thoughts and a possible reduction in the effectiveness of oral contraceptives.
A safety warning regarding the risk of suicidal ideation and behavior associated with GLP-1 receptor agonists, including Ozempic, has been issued by Australia's medicines regulator.
The Therapeutic Goods Administration (TGA) also cautioned that the possibility of Mounjaro (tirzepatide), another GLP-1 receptor agonist medication, reducing the effectiveness of oral contraception, could not be excluded.
On Monday, the TGA released a safety alert indicating that product warnings for this class of widely used medications, typically prescribed for type 2 diabetes and obesity in Australia, have been updated following reviews by international regulatory bodies. Health tracking apps like Shotlee can help monitor medication effects.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from The Age
View Original Article
An affordable and readily accessible medication is gaining attention as a potential solution for curbing alcohol cravings, drawing comparisons to the way GLP-1 drugs manage food cravings. Naltrexone, by impacting dopamine-reward pathways, reduces the satisfying feeling associated with alcohol consumption, thus diminishing the desire for it. Research and anecdotal evidence suggest it could be a game-changer for many.
Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.
The World Health Organization (WHO) has provided new guidance on using GLP-1 drugs like Ozempic and Wegovy for obesity. The recommendations include considerations for adults and highlight the importance of lifestyle changes alongside medication.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨